Close menu




Biotech

Photo credits: pixabay.com

Commented by André Will-Laudien on October 24th, 2025 | 07:35 CEST

BioNxt Solutions advances sublingual MS therapy into decisive development phase

  • Biotechnology
  • Biotech
  • patents
  • Innovations

BioNxt Solutions is on the verge of a decisive step in the development of its novel sublingual cladribine formulation for the treatment of multiple sclerosis. Following successful small-animal studies, the Company is now launching a large-scale animal study to optimize dosage ahead of the planned human bioequivalence study in 2026. The orally soluble thin-film technology is designed to enable faster drug absorption, greater bioavailability, and easier administration. At the same time, BioNxt is securing patent protection in key global markets, further strengthening its position in the competitive field of advanced drug delivery systems. With its focus on patient-friendly, precise, and effective therapies, BioNxt could set a new standard in MS treatment. A promising setup for the coming months. What opportunities does the Company offer dynamic investors?

Read

Commented by Carsten Mainitz on October 23rd, 2025 | 07:25 CEST

AI hidden gem NetraMark Holdings is poised for a price surge, TeamViewer crash, and Novo Nordisk supervisory board resigns! What to do?

  • AI
  • Biotechnology
  • Biotech
  • Pharma
  • Software

Artificial intelligence (AI) is widely regarded as a key technology with enormous potential across all industries. The use of AI opens up new opportunities, particularly in the biotechnology and pharmaceutical industries: from faster identification of potential active ingredients to more precise diagnostics and the automation of complex laboratory processes. Companies that make targeted use of AI gain competitive advantages in a highly competitive environment. Following a broad-based bull market, it is worth exploring promising second-tier players.

Read

Commented by Nico Popp on October 22nd, 2025 | 07:00 CEST

Important piece of the puzzle in the fight against cancer: Vidac Pharma, Roche, Merck & Co.

  • Biotechnology
  • Biotech
  • Pharma
  • Cancer
  • Technology
  • Innovations

The pharmaceutical market is enormous - and continues to grow. Market research institute Evaluate forecasts an increase to around USD 1.7 trillion by 2030, representing an annual growth rate of 7.7%. Oncology promises the highest sales, at around USD 300 billion. However, there is no single approach. Instead, new modalities and technologies such as antibody-drug conjugates (ADCs), cell and gene therapies, and radiopharmaceuticals are transforming the industry and gaining significant traction. One thing is clear: progress in the biotech sector is increasingly achieved through the combination of active ingredients and technologies. What role does the biotech company Vidac Pharma play in this?

Read

Commented by André Will-Laudien on October 21st, 2025 | 07:45 CEST

AI boom and DAX fireworks! Another 100% with NetraMark, Bayer, and Novo Nordisk

  • AI
  • Biotechnology
  • Biotech
  • Pharma

Savvy investors are already taking notice! Artificial intelligence is revolutionizing drug research and radically reducing development costs. Algorithms are discovering molecular patterns that even the most experienced researchers would overlook, thus accelerating the path from laboratory to patient. Whether in oncology, rare diseases, or metabolic disorders, big data-driven models now enable more precise drug predictions and more realistic simulations of clinical outcomes. Those who understand AI can profit handsomely from the next biotech boom. You just have to muster the courage to finally get involved!

Read

Commented by Nico Popp on October 21st, 2025 | 07:10 CEST

Biotech investors should know these suppliers: Thermo Fisher Scientific, BioNxt, AptarGroup

  • Biotechnology
  • Biotech
  • Pharma

While new drugs dominate the headlines, it is often suppliers and service providers that deliver solid long-term returns. Three examples: Thermo Fisher Scientific, BioNxt Solutions, and AptarGroup - all key enablers for pharmaceutical and biotech companies. We present their business models and markets, highlighting where investors can spot particular opportunities – especially BioNxt, which occupies exciting niches with its innovations.

Read

Commented by Armin Schulz on October 20th, 2025 | 07:05 CEST

Why this structural change in medicine makes Novo Nordisk, PanGenomic Health, and Pfizer must-haves

  • Healthcare
  • Biotechnology
  • healthtech
  • Pharma
  • Innovations

The medicine of tomorrow does not think in terms of diseases but in terms of opportunities. A radical shift from repair to proactive prevention is revolutionizing the healthcare sector and opening up massive areas of growth. The focus is on personalized, data-driven solutions that improve quality of life and combat widespread diseases costing billions. This structural transformation is creating clear winners, led by pioneers who have mastered the new logic of the healthcare market. Three companies that embody this trend and make it tangible for investors are Novo Nordisk, PanGenomic Health, and Pfizer.

Read

Commented by Fabian Lorenz on October 17th, 2025 | 07:15 CEST

Acquisition of Vidac Pharma and Evotec? USD 400 billion at stake for Pfizer, Merck & Co!

  • Biotechnology
  • Biotech
  • Pharma

Alarm bells are ringing in Big Pharma! Donald Trump appears serious about reducing drug prices. At the same time, patents on blockbuster drugs are expiring, threatening a USD 400 billion revenue shortfall. Pfizer, Merck, and Co. must refill their pipelines. The acquisition merry-go-round is expected to spin even faster in the coming years. Among the potential takeover targets is Vidac Pharma. The Company is still attractively priced, but if its new approach to fighting cancer proves successful in early clinical trials, a multiplication could be possible. And what about Evotec? The Hamburg-based company has repeatedly been traded as a takeover candidate in recent years. However, data and patents are offset by internal problems.

Read

Commented by Armin Schulz on October 16th, 2025 | 07:20 CEST

Investors take note: BioNxt Solutions builds on blockbusters from Novo Nordisk and Merck - and has another ace up its sleeve in oncology

  • Biotechnology
  • Biotech
  • Pharma
  • Cancer
  • blockbuster
  • Technology

In the biotech sector, a single technology can often determine success or failure. Canadian-German company BioNxt Solutions is taking a different approach, relying on three pillars, each targeting major markets and advancing established blockbusters from leading pharmaceutical companies. October has already brought decisive progress, from accelerated patent protection to concrete milestones in development. These concentrated positive signals show that BioNxt Solutions not only has a promising concept, but also the strategy and operational strength to turn it into value. A closer analysis is worthwhile.

Read

Commented by Fabian Lorenz on October 16th, 2025 | 07:05 CEST

Takeover fever and AI Opportunities: BioNTech, Novo Nordisk, PanGenomic Health

  • Biotechnology
  • AI
  • healthtech
  • Sustainability
  • plantbased

The pharmaceutical and biotech sector is buzzing with takeover activity. Following the announcement of a billion-dollar acquisition in the US, Novo Nordisk has announced its next deal, eyeing a potential best-in-class therapeutic for several rare diseases. Meanwhile, PanGenomic Health is positioning itself in the billion-dollar market for alternative medicine and dietary supplements, leveraging AI to provide added value to customers and capture market share. If successful, the stock could be significantly undervalued. BioNTech's acquisition of CureVac has now been completed, ending CureVac's period of suffering. In the process, BioNTech secures patents and elegantly resolves ongoing legal disputes.

Read

Commented by Nico Popp on October 16th, 2025 | 07:00 CEST

Who definitely deserves credit in the fight against cancer: NetraMark, Moderna, BioNTech

  • Biotechnology
  • AI
  • Biotech
  • Cancer

Two biotech pioneers, Moderna and BioNTech, are back in the spotlight after their COVID-19 vaccine success - this time in a race to develop innovative cancer therapies. Both companies rely on mRNA technology to develop personalized cancer vaccines. Speed is crucial here: whoever brings effective treatments to market first could secure billions in market share. At the same time, AI startup NetraMark is entering the stage with novel data analysis that could significantly accelerate research and shape medical progress. We shed light on what is currently driving both the research community and investors.

Read